New Data Evaluating KEYTRUDA ® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Based on Initial Results Presented at 2016 ASCO Annual Meeting, Merck Has Initiated Two Phase 3 Studies < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced findings from an initial proof-of-concept study of
KEYTRUDA < sup > ® < /sup > (pembrolizumab), the company ’s anti-PD-1 therapy,
combined with standard treatments, one with bevacizumab and others
without, in non-small cell lung cancer (NSCLC) including chemotherapy in
previously untreated patients with NSCLC; the study showed overall
response rates (ORR) ranging from 48 to 7 1 percent, depending on the
therapy used. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div...

Source: Merck.com - Research and Development News - June 4, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK Keytruda Lung Cancer MSD Source Type: news